A biopharmaceutical royalty company that developed respiratory medicines in partnership with GlaxoSmithKline, including the Ellipta inhaler products Breo and Anoro, and now earns ongoing royalties from those drugs. It was born in 2014 when the drug developer Theravance split in two: the research-and-development arm became Theravance Biopharma, while the royalty business took the name Innoviva. The name blends "innovation" and "vival"—a nod to the company's core role of keeping proven medicines alive in the market.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +655.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.